Global COPD Drugs Market: Analysis By Drug Type (Combination Therapy, Anticholinergics, Beta-Agonist, Inhaled Corticosteroids, Others), Pipeline Drugs, By Region, By Country (2019 Edition)- Forecast to 2023

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $2,400	255 Pages	Azoth Analytics	February, 2019	AZAN15901789

Best Price Guarantee
Price	from $2,400
Length	255 Pages
Publisher	Azoth Analytics
Published Date	February, 2019
SKU	AZAN15901789

Global COPD Drugs Market: Analysis By Drug Type (Combination Therapy, Anticholinergics, Beta-Agonist, Inhaled Corticosteroids, Others), Pipeline Drugs, By Region, By Country (2019 Edition)- Forecast to 2023

Executive Summary

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of COPD Drugs Market. The report analyses the COPD Drugs Market By Drug Type (Combination Therapy Drugs, Anticholinergics, Beta-Agonist, Inhaled Corticosteroids, and Others). The report analyses the COPD Drugs Market, By Region (North America, Europe, Asia Pacific, Rest of the World) and By Country (U.S., Canada, Germany, U.K, France, Italy, China, Japan, India) for the historical period of 2013-2017 and the forecast period of 2018-2023. This report also includes pipeline analysis for few COPD drugs.

According to Azoth Analytics research report “Global COPD Drugs Market: Analysis By Drug Type (Combination Therapy Drugs, Anticholinergics, Beta-Agonist, Inhaled Corticosteroids, Others), Pipeline Drugs, By Region, By Country (2019 Edition): Forecast to 2023 - By Region (North America, Europe, APAC, ROW), By Country (U.S., Canada, Germany, U.K, France, Italy, China, Japan, India)”, the COPD drugs market is projected to display robust growth represented by a CAGR of 2.47% during 2018 – 2023.

Over the recent years, COPD Drugs market has been witnessing growth on account of several driving factors including growing prevalence of COPD associated diseases, rising patient population, and increase in availability of novel combination therapy drugs. Moreover, increasing awareness regarding COPD, high smoking prevalence, rising pollution level, growing medical spending, favorable government initiatives, public private partnership have been driving the market growth. In addition, rising geriatric population, increasing global healthcare expenditure and technological advancements in pharmaceuticals research, and growing scope in middle and low income countries with large patient population is anticipated to impel the market growth of the COPD drugs market. However, growing portfolio of generic COPD drugs, and patent expiration of few innovator drugs in upcoming years are expected to hinder the market performance during forecasted period.

In this research report, the market is segmented on the basis of drug type. By drug type, the combination therapy COPD drugs are predicted to hold their dominant position in the market, especially LABA/LAMA and triple combination ICS/LABA/LAMA market is expected to gain more traction in forecasted period. Amongst the regions, North America accounts for the largest regional share in the global COPD drugs market in 2017. The largest share of North America is attributed to presence of enormous number of patient base and more emphasis towards prescribed branded drugs.

The report titled “Global COPD Drugs Market: Analysis By Drug Type (Combination Therapy Drugs, Anticholinergics, Beta-Agonist, Inhaled Corticosteroids, Others), Pipeline Drugs, By Region, By Country (2019 Edition): Forecast to 2023 - By Region (North America, Europe, APAC, ROW), By Country (U.S., Canada, Germany, U.K, France, Italy, China, Japan, India” has covered and analysed the potential of COPD drugs market and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the COPD drugs market. Additionally, the report also highlights market entry strategies for various companies across the globe along with pipeline and product analysis.

Scope of the Report

Global COPD Drugs Market (Actual Period: 2013-2017, Forecast Period: 2018-2023)

COPD Drugs Market– Size, Growth, Forecast
Analysis By Drug Type - Combination Therapy COPD Drugs, Anticholinergics COPD Drugs, Beta-Agonist COPD Drugs, Inhaled Corticosteroids COPD Drugs, and Other COPD Drugs.

Regional COPD Drugs Market – North America, Europe, Asia Pacific, Rest of the World (Actual Period: 2013-2017, Forecast Period: 2018-2023)

COPD Drugs Market– Size, Growth, Forecast
Analysis By Drug Type - Combination Therapy COPD Drugs, Anticholinergics COPD Drugs, Beta-Agonist COPD Drugs, Inhaled Corticosteroids COPD Drugs, and Other COPD Drugs.

Country Analysis – U.S., Canada, Germany, U.K, France, Italy, China, Japan, India (Actual Period: 2013-2017, Forecast Period: 2018-2023)

COPD Drugs Market– Size, Growth, Forecast
Analysis By Drug Type - Combination Therapy COPD Drugs, Anticholinergics COPD Drugs, Beta-Agonist COPD Drugs, Inhaled Corticosteroids COPD Drugs, Other COPD Drugs.

Other Report Highlights

Pipeline Analysis- PT010, Duaklir, Nemiralisib, Danirixin.
Product Analysis.
Market Dynamics – Drivers and Restraints.
Market Trends.
Porter Five Forces Analysis.
SWOT Analysis.
Company Analysis - Glaxo SmithKline, AstraZeneca, Boehringer-Ingelheim, TEVA Pharmaceuticals, Chiesi Pharmaceuticals, Novartis, Merck, Cipla, Mylan, Vectura, Sunovion

1. Research Methodology
2. Executive Summary
3. Strategic Recommendation
4. COPD Drugs Products Outlook: Table 1: Management of COPD
5. Global COPD Drugs Market: Growth and Forecast: 5.1 By Value (2013-2017); Table 2: Global COPD Drugs Market Size, By Value, 2013-2017 (USD Million); Table 3: Smoking Prevalence Among Adults, By Gender, 2015; Table 4: Cigarette Sales Share, By Region, 2017 (% of total); Table 5: Deaths Due To Air Pollution, By Disease Type, 2016; Table 6: Percentage of NCD Cases Due to Air Pollution, 2016; Table 7: Global PM2.5 air pollution, mean annual exposure, 2012-2016; Table 8: Global Aged Population(Above 65), By Country, 2017 (% of total); Table 9: Global Aged Population (Above 65), 2013-2017 (% of total); Table 10: Global Overweight Population (Age above 18), 2013-2016 (% of total); Table 11: Global Overweight Population (Age above 18), By Sex, 2016 (% of total); Table 12: COPD Facts and Figures; Table 13: Generic Market Value Share, In 2006 (Left) &2016 (Right), By Region; Table 14: Healthcare Expenditure (Share of GDP), By Selected Country, 2013-2017 (In %); Table 15: Expected Global Medical Spending in 2020, By Product Type, (% of Total); Table 16: Expected Global Medical Spending in 2020, By Region, (% of Total); Table 17: COPD DAYLs Per 100000, By Country, All Sex, All Age,2017; Table 18: GDP Per Capita PPP, By Region, 2018 (in Thousand USD); Table 19: Global Expected Healthcare Industry Outlook; Table 20: Regional Expected Healthcare Industry Growth Rate By Year 2020; Table 21: Regional Expected Healthcare Industry Growth Rate By Year 2020; 5.2 By Value (2018-2023)
6. Global COPD Drugs Market: Segmental Analysis: 6.1 Global COPD Drugs Market Size, By Drug Type: Breakdown (%); 6.1.1 Global COPD Drugs Market Size, By Drug Type, 2017 (%); Table 22: Global COPD Drugs Market Size, By Drug Type, 2017 (%); 6.1.2 Global COPD Drugs Market Size, By Drug Type, 2023 (%); Table 23: Global COPD Drugs Market Size, By Drug Type, 2023F (%); 6.2 Global Combination Therapy COPD Drugs Market Size, By Value (2013-2023); Table 24: Global Combination Therapy COPD Drugs Market, By Value, 2013-2017 (USD Million); Table 25: Global Combination Therapy COPD Drugs Market, By Value, 2018-2023(USD Million); 6.3 Global Anticholinergics COPD Drugs Market Size, By Value (2013-2023); Table 24: Global Combination Therapy COPD Drugs Market, By Value, 2013-2017 (USD Million); Table 25: Global Combination Therapy COPD Drugs Market, By Value, 2018-2023(USD Million); 6.4 Global Beta- Agonist COPD Drugs Market Size, By Value (2013-2023); Table 24: Global Combination Therapy COPD Drugs Market, By Value, 2013-2017 (USD Million); Table 25: Global Combination Therapy COPD Drugs Market, By Value, 2018-2023(USD Million); 6.5 Global ICS COPD Drugs Market Size, By Value (2013-2023); Table 30: Global ICS COPD Drugs Market, By Value, 2013-2017 (USD Million); Table 31: Global ICS COPD Drugs Market, By Value, 2018-2023(USD Million); 6.6 Global Other COPD Drugs Market Size, By Value (2013-2023); Table 32: Global Other COPD Drugs Market, By Value, 2013-2017 (USD Million); Table 33: Global Other COPD Drugs Market, By Value, 2018-2023(USD Million); 6.6 Global COPD Drugs: Market Attractiveness, By Drug Type; Table 34: Global Market Attractiveness, By Product Type, 2023F
7. Global COPD Drugs Market: Regional Analysis: 7.1 Global COPD Drugs Market Size, By Region : Breakdown (%); 7.1.1 Global COPD Drugs Market Size, By Region, 2017 (%); Table 35: Global COPD Drugs Market Size, By Region, 2017 (%); 7.1.2 Global COPD Drugs Market Size, By Region, 2023 (%); Table 36: Global COPD Drugs Market Size, By Region, 2023F (%)
8. North America COPD Drugs Market: Growth and Forecast: 8.1 North America COPD Drugs Market: Segmental Analysis; Table 37: North America COPD Drugs Market, By Value, 2013-2017 (USD Million); Table 38: United States Spending on Medicines, 2013-2017 (In USD Billion); Table 39: Patented and Non-Patented Drugs Sales in Canada, 2013-2016 (USD Billion); Table 40: North America, Smoking Prevalence, Age 15+, 2013-2016; Table 41: North America, Smoking Prevalence, Age 15+, 2013-2016; Table 42: United States health care expenditure per capita,2013-2016(USD); Table 43: Canada health care expenditure per capita,2013-2016(USD); Table 44: North America population aged 65 and above, 2013-2017 (% of total); Table 45: North America Healthcare Cost Per Capita, 2017 (USD); Table 46: North America GDP per Capita, 2013-2017 (USD); Table 47: North America COPD Drugs Market, By Value, 2018-2023 (USD Million); 8.2 North America COPD Drugs Market Size, By Drug Type: Breakdown (%); 8.2.1 North America COPD Drugs Market Size, By Drug Type, 2017 (%); Table 48: North America COPD Drugs Market Size, By Drug Type, 2017 (%); 8.2.2 North America COPD Drugs Market Size, By Drug Type, 2023 (%); Table 49: North America COPD Drugs Market Size, By Drug Type, 2023F (%); 8.3 North America Combination Therapy COPD Drugs Market Size, By Value (2013-2023); 8.4 North America Anticholinergics COPD Drugs Market Size, By Value (2013-2023); 8.5 North America Beta- Agonist COPD Drugs Market Size, By Value (2013-2023); 8.6 North America ICS COPD Drugs Market Size, By Value (2013-2023); 8.7 North America Other COPD Drugs Market Size, By Value (2013-2023); 8.9 North America COPD Drugs Market: Country Analysis (U.S and Canada); 8.9.1 U.S COPD Drugs Market, By Value (2013-2023); Table 54: USA COPD Drugs Market, By Value, 2013-2017 (USD Million); 8.9.2 U.S COPD Drugs Market, By Drug Type, By Value (2013-2023); Table 55: USA COPD Drugs Market, By Value, 2018-2023(USD Million); Table 56: Smoking Prevalence, Age 15+, 2012-2016; Table 57: Canada, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2012-2016; Table 58: United States Per Capita Spending on Medicines, 2013-2017 (In USD); Table 59: Pharmacy & Drug Store Sales in United States, 2013-2016 (In USD Billion); Table 60: Medical and Healthcare Research & Development Spending, 2013-2016 (In USD Million); Table 61: U.S., Population ages 65 and above, 2013-2017 (% of total); Table 62: U.S., Population ages 65 and above, Forecast (In Millions); Table 63: U.S., Per Capita Expenditure on Healthcare, 2012-2018E (In USD); Table 64: U.S., GDP (Current USD), 2013-2017 (In USD Trillion); Table 65: USA COPD Drugs Market Size, By Drug Type, 2017 (%); Table 66: USA COPD Drugs Market Size, By Drug Type, 2023F (%); Table 67: USA COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million); Table 68: USA COPD Drugs Market, By Drug Type, By Value, 2018-2023(USD Million); 8.9.3 Canada COPD Drugs Market, By Value (2013-2023); Figure 69: Canada COPD Drugs Market, By Value, 2013-2017 (USD Million); 8.9.4 Canada COPD Drugs Market, By Drug Type, By Value (2013-2023); Figure 70: Canada COPD Drugs Market, By Value, 2018-2023(USD Million); Table 71: Percentage Change in Deaths Between, 2007–2017 Due to Respiratory Diseases; Table 72: Canada, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2012-2016; Table 73: Canada, Smoking Prevalence, Age 15+, 2012-2016; Table 74: Number of Retail Pharmacies in Canada, 2013-2017; Table 75: Number of Hospitals Establishments in Canada, By Province, 2015; Table 76: Canada, Expenditure on Health as a share of GDP, 2012-2017 (in %); Table 77: Canada, Per Capita Healthcare Expenditure, 2012-2017 (USD); Table 78: Canada, Population ages 65 and above, 2012-2017 (% of total); Table 79: Canada COPD Drugs Market Size, By Drug Type, 2017 (%); Table 80: Canada COPD Drugs Market Size, By Drug Type, 2023F (%); Table 81: Canada COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million)
9. Europe COPD Drugs Market: Growth and Forecast: 9.1 Europe COPD Drugs Market: Segmental Analysis; Table 82: Europe COPD Drugs Market, By Value, 2013-2017 (USD Million); Table 83: Europe Health Expenditure, By Select Country, 2016 (% of GDP); Table 84: Europe Population ages 65 years and above (% of total population), 2013-17; Table 85: European Union, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2012-2016; Table 86: European Union, Smoking Prevalence, Age 15+, 2012-2016; Table 87: Cause of Death, EU-28, 2015, Per 1000000 inhabitants, Both Sex; Table 88: Europe, COPD Prevalence, By Selected Countries, 2017, (In Million); Table 89: Mean Average Age At Which Majority of Population Affected By COPD, By Region; Table 90: Europe COPD Drugs Market, By Value, 2018-2023 (USD Million); 9.2 Europe COPD Drugs Market Size, By Drug Type: Breakdown (%); 9.1.2 Europe COPD Drugs Market Size, By Drug Type, 2017 (%); Table 91: Europe COPD Drugs Market Size, By Drug Type, 2017 (%); 9.1.3 Europe COPD Drugs Market Size, By Drug Type, 2023 (%); Table 91: Europe COPD Drugs Market Size, By Drug Type, 2017 (%); 9.3 Europe Combination Therapy COPD Drugs Market Size, By Value (2013-2023); 9.4 Europe America Anticholinergics COPD Drugs Market Size, By Value (2013-2023); 9.5 Europe America Beta- Agonist COPD Drugs Market Size, By Value (2013-2023); 9.6 Europe America ICS COPD Drugs Market Size, By Value (2013-2023); 9.7 Europe America Other COPD Drugs Market Size, By Value (2013-2023); Table 93: Europe COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million); Table 94: Europe COPD Drugs Market Size, By Countries, 2017 (%); Table 95: Europe COPD Drugs Market Size, By Countries, 2023F (%); 9.8 Europe COPD Drugs Market: Country Analysis (Germany, France, U.K, Italy); 9.8.1 Germany COPD Drugs Market, By Value (2013-2023); Table 96: Germany COPD Drugs Market, By Value, 2013-2017 (USD Million); 9.8.2 Germany COPD Drugs Market, By Drug Type, By Value (2013-2023); Table 96: Germany COPD Drugs Market, By Value, 2013-2017 (USD Million); Table 98: Germany COPD Prevalence, 2013-2017, 2018E-20123E, (in Millions); Table 99: PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2012-2016; Table 100: Germany, Population ages 65 and above, 2012-2017 (% total); Table 101: Germany, Spending on Healthcare, 2015 & 2040E, (USD Per Person); Table 102: Germany, Healthcare Related Statistics, 2017; Table 103: Germany, Smoking Prevalence, Age 15+, 2012-2016, (% of Total); Table 104: Germany, Percentage Change In Cause of Death Between 2007-2017; Table 105: Germany COPD Drugs Market Size, By Drug Type, 2017 (%); Table 106: Germany COPD Drugs Market Size, By Drug Type, 2023F (%); Table 107: Germany COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million); 9.8.4 France COPD Drugs Market, By Value (2013-2023); Table 108: France COPD Drugs Market, By Value, 2013-2017 (USD Million); 9.8.5 France COPD Drugs Market, By Drug Type, By Value (2013-2023); Table 109: France COPD Drugs Market, By Value, 2018-2023(USD Million); Table 110: France, COPD Prevalence, 2013-2017, 2018E-20123E, (in Millions); Table 111: France, Smoking Prevalence, Age 15+, 2012-2017, (% of Total); Table 112: France, Healthcare Infrastructure Related Statistics; Table 113: France, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2017; Table 114: France, Health Expenditure, (% of GDP), 2012-2015 (USD); Table 115: France, Population Ages 65 and Above (% of total), 2012-2017; Table 116: France, Cause of Death, 2017, (% of Total); Table 117: France, Spending on Healthcare, 2015 & 2040, (USD Per Person); Table 118: France COPD Drugs Market Size, By Drug Type, 2017 (%); Table 119: France COPD Drugs Market Size, By Drug Type, 2023F (%); Table 120: France COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million); 9.8.7 UK COPD Drugs Market, By Value (2013-2023); Table 121: U.K COPD Drugs Market, By Value, 2013-2017 (USD Million); 9.8.6 UK COPD Drugs Market, By Drug Type, By Value (2013-2023); Table 122: U.K COPD Drugs Market, By Value, 2018-2023(USD Million); Table 123: Germany, COPD Prevalence, 2013-2017, 2018E-20123E, (in Millions); Table 124: U.K, Health Expenditure, (% of GDP), 2013-2017 (USD); Table 125: U.K, Population Ages 65 and Above (% of total), 2012-2017; Table 126: U.K, Population Ages 65 and Above (% of total), 2012-2017; Table 127: U.K, Spending on Healthcare, 2015 & 2040, (USD Per Person); Table 128: UK, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2012-2017; Table 129: UK, Smoking Prevalence (% of Total), 2012-2017; Table 130: U.K COPD Drugs Market Size, By Drug Type, 2017 (%); Table 131: U.K COPD Drugs Market Size, By Drug Type, 2023F (%); Table 132: U.K COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million); 9.8.7 Italy COPD Drugs Market, By Value (2013-2023); Table 133: Italy COPD Drugs Market, By Value, 2013-2017 (USD Million); 9.8.8 Italy COPD Drugs Market, By Drug Type, By Value (2013-2023); Table 134: Italy COPD Drugs Market, By Value, 2018-2023(USD Million); Table 135: Italy COPD Prevalence, 2013-2017, 2018E-2023E, (in Millions); Table 136: Italy, Health Expenditure, (% of GDP), 2013-2017 (USD); Table 137: Italy, Population Ages 65 and Above (% of total), 2012-2017; Table 138: Italy, Healthcare Infrastructure Related Statistics; Table 139: Italy, Spending on Healthcare, 2015 & 2040, (USD Per Person); Table 140: Italy, Smoking Prevalence, Age 15+, 2012-2016; Table 141: Italy, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter) 2012-2016; Table 142: Italy COPD Drugs Market Size, By Drug Type, 2017 (%); Table 143: Italy COPD Drugs Market Size, By Drug Type, 2023F (%); Table 144: Italy COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million); 10. APAC COPD Drugs Market: Growth and Forecast; 10.1 APAC COPD Drugs Market: Segmental Analysis; Table 145: APAC COPD Drugs Market, By Value, 2013-2017 (USD Million); Table 146: GDP Per Capita in APAC, By Select Country, 2016 (In USD); Table 147: Population ages 65 and above, By Select Country, 2017 (% of total); Table 148: Men Smoking Prevalence in Asia, 2016, (% of Total Population); Table 149: East Asia & Pacific, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2012-2016; Table 150: South Asia, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2012-2016; Table 151: China, Pharmaceuticals Industry Revenue (USD Billion); Table 152: Japan, Total Drugs Market, 2013-2017, USD Billion; Table 153: India Pharma Market, 2015-2017, (USD Billion); Table 154: APAC COPD Drugs Market, By Value, 2018-2023 (USD Million); 10.2 APAC COPD Drugs Market Size, By Drug Type: Breakdown (%); 10.2.1 APAC COPD Drugs Market Size, By Drug Type, 2017 (%); Table 155: APAC COPD Drugs Market Size, By Drug Type, 2017 (%); 10.2.2 APAC COPD Drugs Market Size, By Drug Type, 2023 (%); Table 155: APAC COPD Drugs Market Size, By Drug Type, 2017 (%); 10.3 APAC Combination Therapy COPD Drugs Market Size, By Value (2013-2023); 10.4 APAC Anticholinergics COPD Drugs Market Size, By Value (2013-2023); 10.5 APAC Beta- Agonist COPD Drugs Market Size, By Value (2013-2023); 10.6 APAC ICS COPD Drugs Market Size, By Value (2013-2023); 10.7 APAC Other COPD Drugs Market Size, By Value (2013-2023); Table 157: APAC COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million); Table 158: APAC COPD Drugs Market Size, By Countries, 2017 (%); Table 159: APAC COPD Drugs Market Size, By Countries, 2023F (%); 10.8 APAC COPD Drugs Market: Country Analysis (China, Japan, and India); 10.8.1 China COPD Drugs Market, By Value (2013-2023); Table 160: China COPD Drugs Market, By Value, 2013-2017 (USD Million); Table 161: China COPD Drugs Market, By Value, 2018-2023(USD Million); Table 162: China, Smoking Prevalence, Age 15+, % of Total Population, 2012-2016; Table 163: China, Tobacco Attributable Deaths, 2030; Table 164: China, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2012-2016; Table 165: Beijing annual PM2.5 air pollution levels, 2013-2017, ( in micrograms per cubic meter of air); Table 166: China Co2 Emissions, 2013-2016 (Billion Metric Tons); Table 167: China, Population Above 65 (% of Total), 2013-2017; Table 168: China, GDP Growth Per Year, 2015-2019 (In %); Table 169: China, Share of Urban Population, 2012-2017 (In %); Table 170: China, Total Population, 2013-2021F (In Billion); Table 171: China COPD Drugs Market Size, By Drug Type, 2017 (%); Table 172: China COPD Drugs Market Size, By Drug Type, 2023F (%); 10.8.2 China COPD Drugs Market, By Drug Type, By Value (2013-2023); Table 173: China COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million); 10.8.3 Japan COPD Drugs Market, By Value (2013-2023); Table 174: Japan COPD Drugs Market, By Value, 2013-2017 (USD Million); Table 175: Japan COPD Drugs Market, By Value, 2018-2023(USD Million); Table 176: Japan, Population ages 65 and above, 2012-2017 (% of total); Table 177: Japan, Smoking Prevalence, Age 15+, 2012-2016, (% of Total Prevalence); Table 178: Japan, Medical Facilities Outlook; Table 179: Japan Healthcare Expenditure Outlook (%); Table 180: Japan, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2012-2016; Table 181: Japan, GDP Growth Per Year, 2015-2019F (In %); Table 182: Japan COPD Drugs Market Size, By Drug Type, 2017 (%); Table 183: Japan COPD Drugs Market Size, By Drug Type, 2023F (%); 10.8.4 Japan COPD Drugs Market, By Drug Type, By Value (2013-2023); Table 184: Japan COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million); 10.8.5 India COPD Drugs Market, By Value (2013-2023); Table 185: India COPD Drugs Market, By Value, 2013-2017 (USD Million); Table 186: India COPD Drugs Market, By Value, 2018-2023(USD Million); Table 187: India, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2012-2017; Table 188: India, Smoking Prevalence, Age 15+, 2012-2016, (% of Total); Table 189: India, Diseases & Medical Industry Outlook; Table 190: India, Population ages 65 and above, 2013-2017; Table 191: India, Total Population, 2013-2023F (In Billion); Table 192: Pharma Export From India Market, 2013-2017, (USD Billion); Table 193: India COPD Drugs Market Size, By Drug Type, 2017 (%); Table 194: India COPD Drugs Market Size, By Drug Type, 2023F (%); 10.8.6 India COPD Drugs Market, By Drug Type, By Value (2013-2023); Table 195: India COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million); 11. ROW COPD Drugs Market: Growth and Forecast; 11.1 ROW COPD Drugs Market: Segmental Analysis; Table 196: ROW COPD Drugs Market, By Value, 2013-2017 (USD Million); Table 197: South Africa, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2013-2016; Table 198: South Africa, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2013-2016; Table 199: GDP Per Capita in ROW, By Select Country, 2013 (In USD); Table 200: GDP Per Capita in ROW, By Select Country, 2013 (In USD); Table 201: GDP Per Capita in ROW, By Select Country, 2013 (In USD); Table 202: Middle East and North Africa, Population ages 65 and above (% of total); Table 203: ROW COPD Drugs Market, By Value, 2018-2023 (USD Million); 11.2 ROW COPD Drugs Market Size, By Drug Type: Breakdown (%); 11.1.1 ROW COPD Drugs Market Size, By Drug Type, 2017 (%); Table 204: ROW COPD Drugs Market Size, By Drug Type, 2017 (%); 11.1.2 ROW COPD Drugs Market Size, By Drug Type, 2023 (%); Table 205: ROW COPD Drugs Market Size, By Drug Type, 2023F (%); 11.3 ROW Combination Therapy COPD Drugs Market Size, By Value (2013-2023); 11.4 ROW Anticholinergics COPD Drugs Market Size, By Value (2013-2023); 11.5 ROW Beta- Agonist COPD Drugs Market Size, By Value (2013-2023); 11.6 ROW ICS COPD Drugs Market Size, By Value (2013-2023); 11.7 ROW Other COPD Drugs Market Size, By Value (2013-2023); Table 206: ROW COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million); Table 207: Exacerbation During the Study Over a Period of 12 Months (Part B); Table 208: Percentage aged 60 years and over, (2000, 2015, 2030,2050); Table 209: COPD - Major Drugs Sales, By Drug Type, 2017 (USD Million); 12. Global COPD Drugs Market: Pipeline Analysis; Table 210: GSK COPD Drugs Sales, 2018-2023 Estimated, USD Million; Table 211: AstraZeneca COPD Drugs Sales, 2018-2023 Estimated, USD Million; Table 212: Novartis COPD Drugs Sales, 2018-2023 Estimated, USD Million; Table 213: COPD - Major Drugs Sales, By Drug Type, 2017 (USD Million); 13. Global COPD Drugs Market: Market Dynamics; 13.1 Global COPD Drugs Market: Drivers; 13.2 Global COPD Drugs Market: Restrains; 13.3 Global COPD Drugs Market: Trends; 13.4 Global COPD Drugs Market: Product Benchmarking; 13.5 Global COPD Drugs Market: Sales Analysis, By Company; 14. Porter Five Force Analysis; 15. SWOT Analysis; 16. Company Profiles; 16.1 GSK; Table 214: GSK, Revenues, 2013-2017 (USD Million); Table 215: GSK, Revenues, 2013-2017 (USD Million); Table 216: GSK, Revenue, By Segments, 2017(%); Table 217: GSK, Revenue, By Pharmaceuticals Segment, 2017 (USD Million); Table 218: GSK COPD Drugs Patent Expiry Details; Table 219: GSK, Respiratory Segment Expected Revenue By 2023 (USD Million); 16.2 AstraZeneca; Table 220: AstraZeneca, Net Sales, 2013-2017 (USD Million); Table 221: AstraZeneca Revenue, By Segments, 2017(%); Table 222: AstraZeneca Revenue, By Region, 2017(%); 16.3 Boehringer-Ingelheim; Table 223: Boehringer-Ingelheim, Net Sales, 2013-2017 (USD Million); Table 224: Boehringer-Ingelheim, By Segments, 2017(%); Table 225: Boehringer-Ingelheim, By Region, 2017(%); 16.4 Teva Pharmaceuticals; Table 226: Teva Pharmaceuticals, Net Sales, 2013-2017 (USD Million); Table 227: Teva Pharmaceuticals, By Segments, 2017(%); Table 228: Teva Pharmaceuticals, By Region, 2017(%); 16.5 Chiesi Farmaceutici S.p.A.; Table 229: Chiesi Farmaceutici S.p.A. , Net Sales, 2013-2017 (USD Million); Table 230: Chiesi Farmaceutici S.p.A. , By Segments, 2017(%); Table 231: Chiesi Farmaceutici S.p.A. , By Segments, 2017(%); 16.6 Novartis; Table 232: Novartis, Net Sales, 2013-2017 (USD Million); Table 233: Novartis, Revenue, By Segment, 2017(%); Table 234: Novartis, Revenue, By Region, 2017(%); 16.7 Cipla; Table 235: Cipla, Net Sales, 2013-2017 (USD Million); Table 236: Cipla , By Region, 2017(%); 16.8 Mylan; Table 235: Cipla, Net Sales, 2013-2017 (USD Million); Table 236: Cipla , By Region, 2017(%); 16.9 Vectura Group Plc,; Table 235: Cipla, Net Sales, 2013-2017 (USD Million); Table 236: Cipla , By Region, 2017(%); 16.10 Sunovion